Inflammatory Bowel Disease: Emerging Therapies and Future Treatment Strategies.

Biomedicines · 2023 · PMC10452708 · PMID 37626745

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Likewise, a higher percentage of patients in the ontamalimab groups attained CDAI-100 response and clinical remission, but these differences did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.